Cost of diabetes treatment in Mexico
Abstract
Diabetes mellitus, better known simply as "diabetes", is a chronic disease that occurs when elevated blood glucose levels occur because the body stops producing or does not produce enough of the hormone called insulin, or fails use said hormone effectively. Currently 6.4 million Mexicans have a medical diagnosis of DM II, that is, 9.4% of the adult population (20 years and older). However, this figure does not include those who have not been diagnosed or are at high risk of developing the disease. DM II is the second cause of death in Mexico and is among the five leading causes of years of life lived with disabilities. Objective: Evaluate the Cost Effectiveness of Diabetes treatment in Mexico. Material and Method: A systematic review was carried out on the Internet based on articles published in Crossref, PUBMED, JCR, NCBI, SCOPUS, information from government institutions; the search is performed using keywords such as; Cost-Effectiveness and Diabetes. Results: Of a total of 22 references reviewed, 5. (23%) were detected in CROSSREF, 12 (54%) in PUBMED, 5 (23%) were detected from information from government institutions. Conclusion: According to the revised literature, the expense that is made in Mexico for diabetes care is high, but most of that investment is going to treat complications and not prevention.
Downloads
References
Magliano DJ, Zimmet P, Shaw JE. Classification of diabetes mellitus and other categories of glucose intolerance. In: DeFronzo RA, Ferrannini E, Zimmet P, Alberti G, editors. International Textbook of Diabetes Mellitus. 4th ed. Chichester: Wiley-Blackwell; 2015:3-16.
International Diabetes Federation. Complicaciones diabéticas. In: International Diabetes Federation, editor. International Diabetes Federation. Diabetes atlas de la FID, 8th ed. Brussels, Belgium: Federación Internacional de Diabetes; 2017: 82-95.
American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;4Suppl 1:S13-27.
Romero-Martínez M, Shamah-Levy T, Cuevas-Nasu L, Méndez Gómez-Humarán I, Gaona-Pineda EB, Gómez-Acosta LM, et al. Encuesta Nacional de Salud y Nutrición de Medio Camino 2016. Informe final de resultados. Available from: https://ensanut.insp.mx/encuestas/ensanut2016/doctos/informes/ENSANUT2016ResultadosNacionales.pdf [Accessed 7 February 2020].
World Health Organization. Global Health Observatory Data Repository. World Health Organization. Available from: http://apps.who.int/gho/data/?theme=main. [Accessed 3 February 2020].
American Diabetes Association. Economic Costs of Diabetes in the U.S. in 2012. Diabetes Care. 2013;36:1033-46.
International Diabetes Federation. The Economic Impacts of Diabetes. In: International Diabetes Federation, editor. International Diabetes Federation. Diabetes Atlas. 3th ed. Brussels, Belgium: International Diabetes Federation; 2006: 237-266.
International Diabetes Federation. The global picture. In: International Diabetes Federation, editor. International Diabetes Federation. Diabetes Atlas. 7th ed. Brussels, Belgium: International Diabetes Federation; 2015: 47-66.
Barcelo A, Arredondo A, Gordillo–Tobar A, Segovia1 J, Qiang A. The cost of diabetes in Latin America and the Caribbean in 2015: Evidence for decision and policy makers. J. Glob. Health. 2017;7(2):1-15.
Köster I, von Ferber L, Ihle P, Shubert I, Hauner H. The cost burden of diabetes mellitus: the evidence from Germany—the CoDiM Study. Diabetología. 2006;49:1498-1504.
OECD. Service delivery: Defining an equal benefits package and strengthening primary care. In: OECD, editor. OECD Reviews of Health Systems México. Assessment and recommendations 2016. París: OECD Publishing; 2016: 91-116.
México ¿cómo vamos?. Presentación del Semáforo Económico Nacional. Trabajo presentado en la presentación del Semáforo Económico Nacional actualizado al cierre del 2014, México. Available from: http://www.mexicocomovamos.mx/wpcontent/uploads/2015/02/SemaforoNac.pdf. [Accessed 10 February 2020].
Funsalud. Estimación de los costos directos de la DM II. In: Funsalud, editor. Carga económica de la diabetes mellitus en México, 2013. México, D.F.: Funsalud; 2015: 20-39.
Arredondo-López A, de Icaza-del Río E, Orozco-Núñez A, Recamán-Mejía AL, Cabrera-López M, Reyes-Sotelo G. Impacto Económico de la Diabetes en México: Deficiencias y Soluciones. En: Aguilar-Salinas CA, Hernández-Jiménez S, Hernández-Ávila M, Hernández Ávila JE, editores. Acciones para enfrentar la Diabetes: Documento de postura. México, D.F.: Intersistemas; 2014: 269-290.
Arredondo A, De Icaza E. The cost of diabetes in Latin America: evidence from Mexico. Value Health. 2011;14 5 Suppl 1:S85-8.
OECD. Country note: How does health spending in México compare? OECD Health Statistics; 2015. Available from: https://www.oecd.org/els/health-systems/Country-Note-MEXICO-OECD-Health-Statistics-2015.pdf [Accessed 15 February 2020].
Instituto Nacional de Estadística, Geografía e Información. Principales causas de mortalidad por residencia habitual, grupos de edad y sexo del fallecido. Available from: http://www.inegi.org.mx/est/contenidos/proyectos/registros/vitales/mortalidad/tabulados/Con sultaMortalidad.asp [Accessed 20 February 2020]
Secretaria de Salud. NOM-015-SSA2-2010, Para la prevención, tratamiento y control de la diabetes mellitus. Diario Oficial de la Federación, 23 November 2010. Available from: http://www.hgm.salud.gob.mx/descargas/pdf/dirgral/marco_juridico/normas/nom_14.pdf [Accessed 20 February 2020].
Córdova-Villalobos JA, Lee GM, Hernández-Ávila M, Aguilar-Salinas CA, Barriguete-Meléndez JA, Kuri-Morales P, et al. Plan de Prevención Clínica de las Enfermedades Crónicas: sobrepeso, riesgo cardiovascular y diabetes mellitus 2007-2012 y Sistema de Indicadores de Diabetes en México. Rev. Mex. Cardiol. 2009;20(1):42-5.
Díaz de León-Castañeda C, Altagracia-Martínez M, Kravzov-Jinich J, Cárdenas-Elizalde MdelR, Moreno-Bonett C, Martínez-Núñez JM. Cost-effectiveness study of oral hypoglycemic agents in the treatment of outpatients with type 2 diabetes attending a public primary care clinic in Mexico City. Clinicoecon Outcomes Res. 2012;4:57–65.
Barquera S, Campos-Nonato I, Aguilar-Salinas C, Lopez-Ridaura1 R, Arredondo A, Rivera-Dommarco J. Diabetes in Mexico: cost and management of diabetes and its complications and challenges for health policy. Global Health. 2013;9(3):1-9.
Bloom DE, Cafiero ET, Jané-Llopis E, Abrahams-Gessel S, Bloom L, Fathima S, et al. The Global Economic Burden of Noncommunicable Diseases. Ginebra: Foro Económico Mundial. Available from: http://www3.weforum.org/docs/WEF_Harvard_HE_GlobalEconomicBurdenNonCommunicableDiseases_2011.pdf. [Accessed 18 February 2020]
Almeda-Váldes P, García-García E, Aguilar-Salinas CA. Manejo Integral del Paciente con Diabetes Mellitus. In: Aguilar-Salinas CA, Hernández-Jiménez S, Hernández-Ávila M, Hernández Ávila JE, editors. Acciones para enfrentar la Diabetes: Documento de postura. México, D.F.: Intersistemas; 2014: 173-203.
Centro Nacional de Excelencia Tecnológica en Salud. Tratamiento de la Diabetes Mellitus tipo 2 en el primer nivel de Atención: Evidencias y Recomendaciones. Catálogo Maestro de Guías de Práctica Clínica: IMSS-718-14. Available from: http://www.cenetec.salud.gob.mx/descargas/gpc/CatalogoMaestro/718_GPC_Tratamiento_de_diabetes_mellitus_tipo_2_/718GER.pdf. [Accessed 20 February 2020]
Nikolic IA, Stanciole AE, Zaydman M. Beyond Health Alone: the Socioeconomic Impact of NCDs. In: Nikolic IA, Stanciole AE, Zaydman M, autors. Chronic Emergency: Why NCDs Matter. Health, Nutrition Population Discussion Paper Washington, DC: World Bank; 2011: 7-14.
Arredondo A, Orozco E, Alcalde-Rabana J, Navarro J, Azar A. Challenges on the epidemiological and economic burden of diabetes and hypertension in Mexico. Rev. Saúde Pública. 2018;52(23):1-12.
Salas-Zapataa L, Palacio-Mejíab LS, Aracena-Genaoc B, Hernández-Ávilad JE, Nieto-Lópeza ES. Costos directos de las hospitalizaciones por diabetes mellitus en el Instituto Mexicano del Seguro Social. Gac. Sanit. 2018;32(3):209-15.
Macías-Sánchez A, Villarreal-Páez HJ. Sostenibilidad del gasto público: Cobertura y financiamiento de enfermedades crónicas en México. Ens. Rev. Econ. 2018;37(1):99-134.
Gutierrez JP, Garcia-Saiso S, Aracena BM. Mexico's household health expenditure on diabetes and hypertension: What is the additional financial burden? PLoS ONE. 2018:13(7). pii: E0201333.
Arredondo A, Reyes G. Health Disparities from Economic Burden of Diabetes in Middle-income Countries: Evidence from México. PLoS ONE. 2013;8(7). pii: E68443.
Mendoza-Herrera K, Quezada AD, Pedroza-Tobías A, Hernández-Alcaraz C, Fromow-Guerra J, Barquera S. A Diabetic Retinopathy Screening Tool for Low-Income Adults in Mexico. Prev. Chronic Dis. 2017;14. pii: E95.
Gilmer T, Burgos JL, Anzaldo-Campos MC, Vargas-Ojeda A. Cost-Effectiveness of a Technology-Enhanced Diabetes Care Management Program in Mexico. ViHRI. 2019;20:41-6.
